Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hunan Dajiaweikang Pharmaceutical Industry Co EBITDA Margin % Related Terms
Hunan Dajiaweikang Pharmaceutical Industry Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Dajiaweikang Pharmaceutical Industry Co EBITDA Margin % Chart
Hunan Dajiaweikang Pharmaceutical Industry Co Annual Data
Hunan Dajiaweikang Pharmaceutical Industry Co EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Hunan Dajiaweikang Pharmaceutical Industry Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Dajiaweikang Pharmaceutical Industry Co EBITDA Margin % vs Healthcare Providers & Services Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) has a EBITDA Margin % of 3.04% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hunan Dajiaweikang Pharmaceutical Industry Co and its competitors. This is 49% below median its historical median of 6.01. According to the industry distribution chart, Hunan Dajiaweikang Pharmaceutical Industry Co ranks #508 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 76.6%.
Is Hunan Dajiaweikang Pharmaceutical Industry Co's EBITDA Margin % too high?
Hunan Dajiaweikang Pharmaceutical Industry Co's current EBITDA Margin % of 3.04% is 49% below median its 10-year median of 6.01. The Healthcare Providers & Services industry median EBITDA Margin % is 10.19. Hunan Dajiaweikang Pharmaceutical Industry Co's value of 3.04% is 70.2% below this industry median. Based on the distribution chart, Hunan Dajiaweikang Pharmaceutical Industry Co ranks #508 out of 663 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Hunan Dajiaweikang Pharmaceutical Industry Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Dajiaweikang Pharmaceutical Industry Co's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Hunan Dajiaweikang Pharmaceutical Industry Co ranks #508 out of 663 companies for EBITDA Margin %. This places Hunan Dajiaweikang Pharmaceutical Industry Co in the lower half of its industry. The industry median EBITDA Margin % is 10.19. Hunan Dajiaweikang Pharmaceutical Industry Co's value of 3.04% is 70.2% below this benchmark. While the company's 10-year median is 6.01 vs. the industry median of 10.19, Hunan Dajiaweikang Pharmaceutical Industry Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.19, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hunan Dajiaweikang Pharmaceutical Industry Co's current EBITDA Margin % of 3.04% is 70.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hunan Dajiaweikang Pharmaceutical Industry Co and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Dajiaweikang Pharmaceutical Industry Co's current EBITDA Margin % is 3.04%, which is 49% below median its own 10-year median of 6.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Dajiaweikang Pharmaceutical Industry Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.31, compared to a current price of ¥9.00 — trading 26.9% below its estimated fair value. The current EBITDA Margin % is 3.04%, which is 49% below median its 10-year median of 6.01 and 70.2% below the Healthcare Providers & Services industry median of 10.19. Hunan Dajiaweikang Pharmaceutical Industry Co's overall GF Score™ is 68/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126), the current EBITDA Margin % is 3.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) Overvalued in 2026?
Based on GuruFocus' analysis, Hunan Dajiaweikang Pharmaceutical Industry Co stock appears to be undervalued.
The current stock price of ¥9.00 is trading 26.9% below its estimated GF Value™ of ¥12.31.
GuruFocus considers Hunan Dajiaweikang Pharmaceutical Industry Co to be Modestly Undervalued.
Key valuation signals for SZSE:301126:
EBITDA Margin %: 3.04% (49% below median its 10-year median of 6.01)
GF Value™: ¥12.31 vs. price of ¥9.00 (26.9% below fair value)
Industry Position: 70.2% below the Healthcare Providers & Services median (#508 of 663)
No single metric tells the full story. See the SZSE:301126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is engaged in the distribution and retail of pharmaceuticals, biological products, medical equipment and other products.
68GF Score
Get the complete analysis for SZSE:301126
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301126 has been successfully added to your 
